Welcome to our dedicated page for Conmed SEC filings (Ticker: CNMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to CONMED Corporation’s (NYSE: CNMD) U.S. Securities and Exchange Commission filings, with AI-powered tools to help interpret the information. CONMED files a variety of reports under the Securities Exchange Act of 1934, and its common stock is registered on the New York Stock Exchange under the symbol CNMD, as noted in multiple Form 8-K filings.
For this medical equipment company in the surgical and medical instrument manufacturing industry, SEC filings are a primary source for understanding its financial condition, operating performance and strategic actions. Current reports on Form 8-K disclose events such as quarterly and year-to-date financial results, portfolio optimization steps, changes in directors and executive officers, dividend declarations, and share repurchase authorizations. For example, recent 8-K filings describe the announcement of second and third quarter financial results, the intent to exit gastroenterology product lines, the appointment of a new independent director, the resignation of a director, the declaration of a quarterly cash dividend, and a planned transition of the Chief Financial Officer.
Annual reports on Form 10-K and quarterly reports on Form 10-Q, when accessed through this page, contain detailed financial statements, segment information for orthopedic and general surgery, and discussions of items that are later referenced in non-GAAP reconciliations, such as product rationalization costs, operational optimization consulting fees, executive transition costs, legal matters, contingent consideration fair value adjustments, restructuring and related costs, and other specified items. These filings also provide context for guidance on revenue and adjusted diluted earnings per share that CONMED discusses in its press releases and investor presentations.
In addition to giving direct access to the underlying documents, this page uses AI to summarize key points from lengthy filings, highlight important sections, and surface items related to topics such as portfolio changes, capital allocation decisions, and leadership transitions. Users can review CONMED’s historical and current SEC disclosures here, along with AI-generated insights that explain the significance of each filing in clear language.
CONMED Corporation filed its annual 10-K detailing 2025 performance and risks. Consolidated net sales rose to
The business is heavily driven by recurring single-use products, which represented about 78% of orthopedic surgery revenue and 92% of general surgery revenue in 2025. International markets accounted for roughly 32% of consolidated net sales, and no single customer generated more than 10% of revenue.
As of June 30, 2025, non-affiliate market value was approximately
CONMED Corporation filed a current report to let investors know it has released its financial results for the fourth quarter ended December 31, 2025. The company issued a press release on January 28, 2026, and attached it as Exhibit 99.1 to this report.
The filing clarifies that the earnings information in Item 2.02 and the press release are being furnished, not filed, which affects how they are treated under securities laws and how they may be incorporated into other regulatory documents.
CONMED Corporation is sharing an investor presentation as part of its appearance at the J.P. Morgan Healthcare Conference on January 12, 2026. The presentation, furnished as Exhibit 99.1, includes the company’s preliminary 2026 financial guidance and is available on its website in the Investors section under News & Events – Presentations.
The information in this report and the attached presentation is being furnished rather than filed under U.S. securities laws, which means it is not automatically subject to certain liability provisions or incorporated into other filings unless specifically referenced.
CONMED Corporation reported a planned transition of its Chief Financial Officer, Todd Garner. His separation as CFO will be effective on the earlier of March 15, 2026 or the appointment of a new permanent CFO, while he remains employed through November 2, 2026 to support a smooth transition. The company has engaged an executive search firm and begun a comprehensive search for the next CFO.
Garner will receive severance benefits under the company’s Executive Severance Plan in connection with a Qualifying Termination, and will continue to receive his current compensation, benefits, and eligibility for his 2025 annual bonus during the transition period, but will not receive a 2026 annual equity award grant. During the subsequent consulting period, he will receive his current base salary and may earn a pro‑rated 2026 cash bonus, subject to conditions including no termination for cause or breach of agreements. His existing equity awards will continue to vest through November 2, 2026, and the company states that his separation did not result from any disagreement over operations, policies, financial results, or accounting practices.
CONMED Corporation executive Brent Lalomia, Executive VP RA, QA, reported annual changes in indirect ownership of CONMED common stock for the fiscal year ended 12/31/2025. Between January 1, 2025 and December 31, 2025, he acquired 31.626 shares of CNMD common stock through the company’s 401(k) plan at a reported price of $40.6 per share. As of December 31, 2025, his 401(k) plan held a total of 125.232 shares of CONMED common stock, reported as indirectly owned. No derivative securities were reported.
CONMED Corporation reported that it plans to exit its gastroenterology product lines as part of a broader portfolio optimization strategy. The Company announced that this change includes ending its distribution agreement with W.L. Gore & Associates, Inc. for the Gore® VIABIL® biliary stent, effective January 1, 2026, and it expects to exit the rest of its gastroenterology product portfolio as well.
The update was communicated through a press release dated December 5, 2025, which is furnished as an exhibit to this report. The announcement signals a strategic refocus on other parts of CONMED’s business, but the filing does not provide financial details about the gastroenterology products being exited.
CONMED Corp (CNMD)$41.21 per share. Following this sale, the filing shows the officer beneficially owning 0 shares directly.
This is a routine Form 4 disclosure required by U.S. securities laws whenever company insiders buy or sell the company’s stock. It does not, by itself, explain the officer’s reasons for the transaction or signal any change in the company’s business operations.
CONMED Corporation’s Chief Information Officer, Richard Glaze, reported the settlement of restricted stock units in a Form 4 filing. On 11/20/2025, 375 RSUs were converted into shares of common stock at an exercise price of $0 per share, increasing his directly held common stock to 375 shares.
To cover taxes due on this vesting, 118 shares of common stock were disposed of at $40.63 per share, leaving 257 shares of common stock held directly after the withholding. Following the transaction, 750 RSUs remain outstanding, each representing a contingent right to receive one share of CONMED common stock.
CONMED Corporation (CNMD) reported a planned sale of company stock by an affiliate under Rule 144. The notice covers the proposed sale of 257 shares of CNMD common stock through Fidelity Brokerage Services LLC on the NYSE, with an indicated aggregate market value of $10,590.97. The filing states that the issuer had 30,967,954 shares outstanding of the same class at the time referenced.
The 257 shares being sold were acquired on 11/20/2025 through a restricted stock vesting transaction from the issuer, with the consideration classified as compensation. The person for whose account the securities are to be sold must represent that they are not aware of any undisclosed material adverse information about CONMED’s current or prospective operations before proceeding with the sale.
Capital Research Global Investors filed Amendment No. 3 to Schedule 13G on CONMED Corp. (CNMD), reporting beneficial ownership of 1,032,733 shares of common stock, representing 3.3% of the class.
The filer reports sole voting power over 1,032,733 shares and sole dispositive power over 1,032,733 shares, with no shared power. The filing identifies the reporting person type as IA (investment adviser). The ownership is certified as acquired and held in the ordinary course and not for the purpose of changing or influencing control.
CRGI notes its 3.3% is based on 30,954,963 shares believed to be outstanding. The date of event requiring the filing is 09/30/2025.